American Century Companies Inc. Increases Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)

American Century Companies Inc. boosted its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 28.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 69,175 shares of the company's stock after purchasing an additional 15,192 shares during the period. American Century Companies Inc. owned about 0.25% of Castle Biosciences worth $1,844,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in CSTL. China Universal Asset Management Co. Ltd. grew its stake in Castle Biosciences by 11.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,939 shares of the company's stock valued at $158,000 after acquiring an additional 604 shares in the last quarter. Y Intercept Hong Kong Ltd increased its holdings in shares of Castle Biosciences by 3.6% in the third quarter. Y Intercept Hong Kong Ltd now owns 24,206 shares of the company's stock worth $690,000 after purchasing an additional 845 shares during the last quarter. Truist Financial Corp lifted its position in shares of Castle Biosciences by 4.6% in the fourth quarter. Truist Financial Corp now owns 21,303 shares of the company's stock worth $568,000 after buying an additional 928 shares in the last quarter. Bailard Inc. boosted its stake in Castle Biosciences by 12.5% during the fourth quarter. Bailard Inc. now owns 9,900 shares of the company's stock valued at $264,000 after buying an additional 1,100 shares during the last quarter. Finally, R Squared Ltd purchased a new position in Castle Biosciences during the 4th quarter valued at approximately $42,000. 92.60% of the stock is currently owned by institutional investors.

Insider Activity

In other Castle Biosciences news, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Derek J. Maetzold sold 986 shares of the business's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.03, for a total value of $27,637.58. Following the completion of the transaction, the insider now directly owns 80,818 shares of the company's stock, valued at approximately $2,265,328.54. The trade was a 1.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,071 shares of company stock worth $775,682. 7.20% of the stock is currently owned by corporate insiders.

Castle Biosciences Stock Up 2.1 %

Shares of CSTL stock traded up $0.40 during mid-day trading on Friday, hitting $19.70. The stock had a trading volume of 209,020 shares, compared to its average volume of 377,693. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.64. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84. The firm's 50-day moving average is $22.34 and its two-hundred day moving average is $27.09. The firm has a market capitalization of $568.13 million, a P/E ratio of 98.50 and a beta of 1.11.

Analyst Ratings Changes

CSTL has been the subject of several analyst reports. Stephens reissued an "overweight" rating and issued a $41.00 price objective on shares of Castle Biosciences in a research note on Thursday, January 2nd. Guggenheim set a $30.00 price objective on Castle Biosciences and gave the company a "buy" rating in a report on Friday, March 28th. Finally, Robert W. Baird lifted their target price on Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Castle Biosciences currently has a consensus rating of "Buy" and a consensus price target of $38.75.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.